Cheddar- Coronavirus Latest: Vaccine Distribution on the Horizon & Thanksgiving Travel
November 30, 2020
Dr. Lisa Danzig, infectious disease specialist and Chief Medical Advisor for the COVID-19 Early Treatment Fund spoke with Cheddar about the latest vaccine news and the need for more research on early treatments.
WIRED- How a Medication for OCD Ended Up in a Covid-19 Trial
November 19, 2020
Read the story of how a CETF-funded trial led by researchers at Washington University in St. Louis discovered that a well-known, readily available drug for OCD could be repurposed to prevent COVID-19 complications and save lives.
Yahoo Finance- Tech Entrepreneur Seeks COVID-19 Treatment Using Existing Drugs
July 28, 2020
CETF Founder Steve Kirsch discusses why we can't wait for a COVID-19 vaccine, the importance of researching existing drugs now, and our work to raise funds for outpatient trials to identify effective treatments ASAP.
Silicon Valley entrepreneur and philanthropist Steve Kirsch says a key research avenue is being ignored: the identification of a drug or drugs to prevent progression into serious illness, hospitalization or death in newly infected patients.
If you have COVID-19, Stanford Health Care may be able to help you right away. Stanford is looking for volunteers to take part in a new trial, and it wants to treat patients almost immediately after testing positive. Dr. Prasanna Jagannathan talks with Raj Mathai about the trial and the treatment.
A new clinical trial at Stanford University is part of an emerging movement to find COVID-19 medicines that can be given almost immediately after infection, before the virus gains a firm foothold in the body.
An anxiety-fighting drug that has been on the market for decades could turn out to be a potent weapon in the fight against COVID-19. Early-stage research published in a major journal this month found the antidepressant fluvoxamine may prevent patients with COVID-19 from needing hospital care.
The COVID-19 Early Treatment Fund (CETF), which is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) organization created to ensure the rapid and successful completion of outpatient clinical trials of existing drugs that lead to effective early treatments for COVID-19, today announced the results of a recently funded outpatient clinical trial at Washington University in St. Louis that examined the viability of fluvoxamine in patients with mild COVID-19.
Oops! Something went wrong while submitting the form.
COVID-19 Early Treatment Fund (CETF)
The COVID-19 Early Treatment Fund (CETF) is administered by Rockefeller Philanthropy Advisors, a 501(c)(3) public charity (EIN: 13-3615533). All donations to CETF are tax deductible and go exclusively towards funding outpatient trials.